Beyond Air Inc (XAIR)

Nov 12, 2026

Beyond Air Inc (XAIR) reported record quarterly revenue of $2.3 million for Q2 2027, an increase of approximately 28% year-over-year, alongside an improved gross margin of 8%. The company's second-generation LungFit PH system is currently under FDA review, with audit readiness expected by mid-December and a positive decision anticipated in Q1 2027. Despite a net loss of $7.8 million, Beyond Air reaffirmed its revenue guidance for calendar years 2026 and 2027, bolstered by a growing commercial pipeline and international distribution partnerships.

Nov 11, 2026

Beyond Air (NASDAQ: XAIR) reported record quarterly revenue of $2.3 million for Q3 2026, a 28% year-over-year increase, driven by strong market penetration and hospital agreements for its LungFit PH system. The company is preparing for the commercial launch of its second-generation LungFit PH system, pending FDA approval, and reaffirmed its revenue guidance of $8 million for 2026 and $16-18 million for 2027. Despite a net loss, Beyond Air improved its gross margin and reduced R&D and administrative expenses, focusing on commercial execution over further development of LungFit Go.